Free Trial

10 Best Penny Stocks to Buy Now - 8 of 10

 
 

Scilex (NASDAQ:SCLX)

Number of Upgrades from Top-Ranked Analysts
3 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$8.00 (765.2% Upside)

About Scilex

Scilex logoScilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
6/13/2024Rodman & RenshawInitiated CoverageBuy$13.00
6/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
5/23/2024HC WainwrightLower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
5/3/2024HC WainwrightLower Price TargetBuy ➝ Buy$12.00 ➝ $8.00
12/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
10/13/2023B. RileyInitiated CoverageBuy$4.00
10/9/2023HC WainwrightInitiated CoverageBuy$12.00
 

Protect Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.